triamcinolone acetonide

×

Overview

What is triamcinolone acetonide?

The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone Acetonide Cream USP contains Triamcinolone Acetonide [Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis- (oxy)]-, (11β,16α)-], with the empirical formula C H FO and molecular weight 434.50. CAS 76-25-5.

Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of Triamcinolone Acetonide per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.

What does triamcinolone acetonide look like?

What are the available doses of triamcinolone acetonide?

Sorry No records found.

What should I talk to my health care provider before I take triamcinolone acetonide?

Sorry No records found

How should I use triamcinolone acetonide?

Triamcinolone acetonide cream 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Apply triamcinolone acetonide cream, 0.1% as appropriate, to the affected area two to three times daily. Rub in gently.

Occlusive Dressing Technique

What interacts with triamcinolone acetonide?

Sorry No Records found

What are the warnings of triamcinolone acetonide?

Sorry No Records found

What are the precautions of triamcinolone acetonide?

Sorry No Records found

What are the side effects of triamcinolone acetonide?

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

To report , contact Teligent Pharma, Inc. at 1-856-697-1441, or FDA at 1-800-FDA-1088 or

What should I look out for while using triamcinolone acetonide?

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

What might happen if I take too much triamcinolone acetonide?

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See ).

How should I store and handle triamcinolone acetonide?

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Dispense in well-closed containers as defined in the USP.Keep out of reach of children.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Dispense in well-closed containers as defined in the USP.Keep out of reach of children.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Dispense in well-closed containers as defined in the USP.Keep out of reach of children.Triamcinolone Acetonide Cream USP, 0.1% is supplied in the following: NDC 68071-4168-8 Box of 80 g Store at controlled room temperature 15°-30°C (59°-86°F).Avoid excessive heat. Protect from freezing.Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Revised: 04/2017Triamcinolone Acetonide Cream USP, 0.1% is supplied in the following: NDC 68071-4168-8 Box of 80 g Store at controlled room temperature 15°-30°C (59°-86°F).Avoid excessive heat. Protect from freezing.Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Revised: 04/2017Triamcinolone Acetonide Cream USP, 0.1% is supplied in the following: NDC 68071-4168-8 Box of 80 g Store at controlled room temperature 15°-30°C (59°-86°F).Avoid excessive heat. Protect from freezing.Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Revised: 04/2017Triamcinolone Acetonide Cream USP, 0.1% is supplied in the following: NDC 68071-4168-8 Box of 80 g Store at controlled room temperature 15°-30°C (59°-86°F).Avoid excessive heat. Protect from freezing.Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Revised: 04/2017Triamcinolone Acetonide Cream USP, 0.1% is supplied in the following: NDC 68071-4168-8 Box of 80 g Store at controlled room temperature 15°-30°C (59°-86°F).Avoid excessive heat. Protect from freezing.Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Revised: 04/2017

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Non-Clinical Toxicology

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see ).

General:

Systemic absorption of topical corticosteroids has produced reversible hypo-thalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glycosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequencies of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.

Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

These preparations are not for ophthalmic use.

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

To report , contact Teligent Pharma, Inc. at 1-856-697-1441, or FDA at 1-800-FDA-1088 or

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: